On September 24, 2012, Northwest Biotherapeutics, Inc. (the "Company") filed a Certificate of Amendment to its Seventh Amended and Restated Certificate of Incorporation (the "Certificate of Amendment") with the Secretary of State of Delaware, pursuant to which (i) the number of authorized shares of the Company's blank check preferred stock increased from 20,000,000 to 40,000,000, and (ii) effective September 25, 2012, the Company effected a one-for-sixteen reverse split of its issued and outstanding common stock. The reverse split will not change the number of authorized shares of the Company's common stock. A copy of the Certificate of Amendment is attached hereto as Exhibit 3.1.

On September 26, 2012, the Company issued a press release announcing that on September 25, 2012 at 5:00 p.m. EDT it effected a one (1) for sixteen (16) reverse split of its issued and outstanding common stock (the "Reverse Split") as a first step in a planned public offering of up to $25 million and listing of its common stock on the NASDAQ Capital Market. A copy of the press release is attached hereto as Exhibit 99.1.

(d) Exhibits

Exhibit No. Description
3.1         Certificate of Amendment of the Seventh Amended and Restated Certificate
            of Incorporation of Northwest Biotherapeutics, Inc.

99.1        Press Release of Northwest Biotherapeutics, Inc. dated September 26,
            2012.